摘要
2022年同时发布了造血和淋巴组织肿瘤第5版WHO分类(WHO 2022)以及髓系肿瘤和急性白血病的国际分类共识(ICC 2022),其中均对髓系肿瘤包括骨髓增生异常综合征进行了更新。本文聚焦于骨髓增生异常综合征的关键更新内容,比较了WHO和ICC两种分类的不同之处,并结合临床实际运用进行相关解读。
In 2022,the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors:Myeloid and Histiocytic;Dendritic Neoplasms(WHO 2022)and International Consensus Classification of Myeloid Neoplasms and Acute Leukemias:integrating morphologic,clinical,and genomic data(ICC 2022)were published simultaneously.Myeloid tumors,including myelodysplastic syndromes,were all updated.This article focuses on the key updates of myelodysplastic syndromes,compares the differences between WHO and ICC classification,and puts forward relevant interpretation based on clinical practice.
作者
佟红艳
TONG Hongyan(Myelodysplastic Syndromes Diagnosis and Therapy Center,Department of Hematology,the First Affiliated Hospital,Zhejiang University School of Medicine,Zhejiang Provincial Clinical Research Center for Hematological Disorders,Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy,Zhejiang University Cancer Center,Hangzhou,310003,China)
出处
《临床血液学杂志》
2023年第11期773-778,共6页
Journal of Clinical Hematology
基金
国家自然科学基金(No:81970117、82270146)。
关键词
骨髓增生异常综合征
分型
myelodysplastic syndrome
classification
